Which STIs Can Doxycycline Treat—and Which Can’t It Cure?
The short answer: which STIs doxycycline treats
Doxycycline is a recommended treatment for uncomplicated chlamydia. It is also used in specific, diagnosis-dependent regimens for lymphogranuloma venereum and nongonococcal urethritis. For syphilis, doxycycline may be an alternative for certain nonpregnant people with a penicillin allergy, but penicillin G remains the preferred treatment.
Doxycycline alone is not the recommended treatment for gonorrhea. When gonorrhea is diagnosed and chlamydia has not been excluded, clinicians may add doxycycline for chlamydia coverage. That does not make doxycycline the primary treatment for gonorrhea.
Doxycycline does not treat viral STIs, such as HIV or herpes. It also should not be used as a general-purpose antibiotic for an unexplained genital, rectal, or throat symptom. The appropriate medication and regimen depend on the diagnosed infection, the body site involved, pregnancy status, allergies, and other clinical factors.
Doxycycline post-exposure prophylaxis, or doxy PEP, is a separate use. It is intended to reduce the chance of acquiring certain bacterial STIs after sex; it is not a treatment course for an infection that is already present. Using leftover doxycycline can delay the correct diagnosis and treatment, expose partners to ongoing infection, and contribute to inappropriate antibiotic use.
Chlamydia: a first-line use of doxycycline
For uncomplicated chlamydial infection in adolescents and adults, the CDC-recommended doxycycline regimen is 100 mg by mouth twice daily for 7 days. This recommendation covers infection of the urogenital tract, rectum, and oropharynx. The prescribed course should be completed even if symptoms improve sooner.
Pregnancy changes the treatment decision, so pregnant patients should receive clinician-directed care rather than assuming that the standard nonpregnant regimen applies. Lymphogranuloma venereum, a specific form of chlamydial infection, also requires a different and longer doxycycline regimen: 100 mg twice daily for 21 days. A 7-day course should not be carried over to that diagnosis.
People treated for chlamydia should avoid sex until they have completed a 7-day regimen and until their sex partners have been treated. This helps reduce the chance of passing the infection back and forth. Partners may need evaluation, testing, and treatment even when they have no symptoms.
A routine test of cure is generally not advised for nonpregnant people, unless adherence is uncertain, symptoms continue, or reinfection is suspected. Retesting approximately 3 months after treatment is recommended because repeat infection is common. Persistent symptoms do not prove that treatment failed, and symptom improvement does not prove that the infection has been eradicated; both situations warrant clinical assessment.
Syphilis: an alternative in limited situations
Penicillin G is the preferred treatment for all stages of syphilis. Doxycycline is an alternative only in selected nonpregnant people with a penicillin allergy, and the evidence supporting alternatives is limited. Close clinical follow-up is required when an alternative is used.
The regimen also depends on the stage of infection. For primary or secondary syphilis, the CDC-listed doxycycline alternative is 100 mg by mouth twice daily for 14 days. For late latent syphilis or syphilis of unknown duration, the alternative course is 100 mg twice daily for 28 days. These are diagnosis-specific regimens, not general instructions for treating a possible syphilis exposure.
Pregnancy is a major exception. A pregnant patient with syphilis who is allergic to penicillin should be desensitized and treated with penicillin G rather than switched to doxycycline. Doxycycline should not be viewed as interchangeable with penicillin in this setting.
Possible neurologic or ocular involvement also changes the evaluation and treatment pathway. Neurosyphilis and ocular syphilis require their own clinical assessment and management. Symptoms involving vision, the eyes, the nervous system, or other concerning findings should not be managed with leftover doxycycline or a self-selected alternative.
Doxycycline and STIs
Gonorrhea: why doxycycline alone is not recommended
Doxycycline is not recommended as stand-alone treatment for gonorrhea. For uncomplicated gonorrhea of the cervix, urethra, or rectum, the CDC recommends intramuscular ceftriaxone, with the dose determined by body weight. The choice reflects the need for a regimen that reliably addresses gonorrhea, including concerns about antimicrobial resistance.
Doxycycline may appear in a gonorrhea treatment plan for a different reason. If chlamydial infection has not been excluded, clinicians direct patients to receive doxycycline for chlamydia coverage. In that situation, doxycycline is an addition to the gonorrhea regimen; it is not being used as dependable gonorrhea treatment.
Symptoms from gonorrhea and chlamydia can overlap, and some infections cause no symptoms. A person cannot determine from symptom improvement whether gonorrhea has been eliminated. Testing helps identify the infection and the exposed sites, while clinician-directed treatment addresses each diagnosed infection appropriately.
Taking doxycycline alone after a possible gonorrhea exposure may leave gonorrhea undertreated and allow transmission to partners. It can also make follow-up more difficult if the original diagnosis was never established. Anyone with a positive gonorrhea test, a known exposure, or compatible symptoms should seek clinical evaluation rather than relying on leftover medication.
Other STI-related uses of doxycycline
Doxycycline has additional diagnosis-specific uses in STI care. For lymphogranuloma venereum, the CDC-recommended regimen is doxycycline 100 mg by mouth twice daily for 21 days. This is longer than the regimen used for uncomplicated chlamydia because the conditions are not interchangeable.
Doxycycline is also a CDC-recommended regimen for nongonococcal urethritis, at 100 mg twice daily for 7 days. Nongonococcal urethritis describes urethral inflammation that is not diagnosed as gonorrhea; identifying the cause and assessing for other infections can still be important.
Mycoplasma genitalium requires particular caution. Doxycycline may be used as an initial step in resistance-guided and non-resistance-guided treatment, but doxycycline alone has limited efficacy against this infection. Subsequent treatment depends on resistance information and clinical circumstances. A person with ongoing symptoms after treatment should be reassessed rather than repeating doxycycline without testing.
These examples do not mean that doxycycline treats every infection associated with sexual contact. Its role depends on the organism, the infection site, the clinical diagnosis, and whether another antibiotic is needed as part of the regimen.
Treatment versus doxy PEP prevention
Doxycycline treatment is used after an infection has been diagnosed or when a clinician has determined that a particular regimen is appropriate. Doxy PEP is different: it is a post-exposure prevention strategy intended to reduce acquisition of certain bacterial STIs after sex. A doxy PEP dose is not treatment for an established infection and should not replace diagnostic testing.
The CDC recommends that clinicians discuss doxy PEP with gay, bisexual, and other men who have sex with men and transgender women who had syphilis, chlamydia, or gonorrhea during the previous 12 months. Evidence is insufficient for the CDC to make the same population-level recommendation for other groups, so use outside the studied populations requires individualized clinical judgment.
The CDC doxy PEP regimen is 200 mg as soon as possible within 72 hours after oral, vaginal, or anal sex, with no more than 200 mg in 24 hours. It should be provided as part of comprehensive sexual health care, including testing at exposed sites and reassessment every 3-6 months.
Doxy PEP is intended to reduce acquisition of syphilis and chlamydia and, in some studies, gonorrhea. It does not prevent HIV or herpes. It also does not eliminate the need for testing, partner care, or evaluation of symptoms. Prevention dosing and a full treatment regimen serve different purposes and should not be substituted for one another.
Safe use, testing, partner care, and follow-up
Testing is important because STIs may cause no symptoms, and an infection may be present at a site that was not tested. Depending on sexual exposure, evaluation may need to include genital, rectal, or throat testing. A urine test alone may not answer every clinical question.
Take doxycycline exactly as prescribed and do not share it or save it for a future exposure. Use at least 8 ounces of water with the dose and avoid lying down for 1 hour afterward. Doxycycline should be separated by at least 2 hours from dairy products, antacids, and supplements containing iron, calcium, or magnesium. Gastrointestinal or esophageal irritation and increased sensitivity to sunlight are important possible adverse effects. Pregnancy should be discussed with a clinician before using doxycycline, including for doxy PEP.
Follow-up depends on the infection and the circumstances. For chlamydia, people should avoid sex until the prescribed 7-day regimen is complete and partners have been treated. Retesting approximately 3 months after treatment is recommended because repeat infection is common. A routine test of cure is generally unnecessary for nonpregnant people unless adherence is uncertain, symptoms persist, or reinfection is suspected; pregnancy has different follow-up requirements.
Partner evaluation and treatment help prevent reinfection and further transmission. Testing and follow-up are safer than self-treating because they can distinguish chlamydia, gonorrhea, syphilis, nongonococcal urethritis, and other causes that require different care.
When to seek medical care promptly
Seek clinical care if you have symptoms that could indicate an STI, know that a partner has tested positive, have had a significant sexual exposure, or receive a positive test result. Testing is also appropriate when symptoms continue after treatment or return later, since this may reflect reinfection, an alternate diagnosis, or the need for further evaluation.
Do not use symptom improvement as proof that an infection is gone. Some STIs cause few or no symptoms, while symptoms can improve even when the underlying infection requires additional care. Avoid taking leftover doxycycline before testing when possible, because it may not treat the infection involved and can obscure the clinical picture.
Possible syphilis involving the eyes or nervous system needs prompt evaluation. Eye pain, vision changes, neurologic symptoms, or other concerning findings should not be managed with self-selected doxycycline. These conditions have their own evaluation and treatment pathways.
Pregnant patients with a possible or confirmed STI should contact a clinician promptly because pregnancy changes treatment decisions, particularly for syphilis and doxycycline use. A clinician can select the appropriate test, treatment, partner-management plan, and follow-up based on the infection and the exposed body sites.
Doxycycline is a recommended treatment for uncomplicated chlamydia; the standard course is 7 days, and the full course should be completed even if symptoms improve. It also has specific roles in lymphogranuloma venereum and nongonococcal urethritis, but those require distinct regimens. Doxycycline is not recommended as stand-alone treatment for gonorrhea. When gonorrhea is diagnosed and chlamydia has not been excluded, a clinician may add doxycycline as chlamydia coverage. It does not treat viral STIs such as HIV or herpes.
For syphilis, penicillin G is preferred. Doxycycline may be an alternative only in selected nonpregnant people with a penicillin allergy, with close follow-up and a stage-dependent course; pregnant people with syphilis and penicillin allergy should be desensitized and treated with penicillin G. Possible eye or nervous system involvement requires prompt clinical evaluation.
Doxycycline post-exposure prophylaxis is a prevention strategy intended to reduce the chance of acquiring certain bacterial STIs after sex, not to treat an existing infection. Anyone with symptoms, a known exposure, or a positive test should seek testing and clinician-directed care rather than self-treating with leftover medication. People treated for chlamydia should avoid sex until the regimen is completed and partners have been treated, and retesting about 3 months later is recommended because repeat infection is common.
Publishing organization: Centers for Disease Control and Prevention
Publishing organization: Centers for Disease Control and Prevention
Publishing organization: Centers for Disease Control and Prevention
Questions and comments
Please do not include passwords, medical record numbers, insurance information, financial information, precise addresses, or other confidential or directly identifying information in your message.